Peptide Oral Bioavailability
Challenges and strategies for improving oral peptide delivery, including permeation enhancers, enzyme inhibitors, and formulation approaches.
Peptide Oral Bioavailability
Oral delivery of peptides faces formidable barriers that limit bioavailability to typically 1-5% of the administered dose. Overcoming these barriers is a major goal in peptide therapeutics.
Absorption Barriers
Enzymatic Degradation
The gastrointestinal tract contains proteases (pepsin, trypsin, chymotrypsin, carboxypeptidases) that rapidly degrade peptides. Peptides smaller than 500 Da are particularly susceptible to hydrolysis by brush border peptidases.
Poor Membrane Permeation
Peptides are hydrophilic and often charged, making passive diffusion across lipid membranes unfavorable. Molecular weight above 500 Da significantly reduces passive permeation (Lipinski’s rule).
Low Stability in Gastric Acid
Stomach pH (1.5-3.5) can denature peptides and accelerate acid-catalyzed hydrolysis, particularly for acid-labile bonds like aspartyl-proline linkages.
Permeation Enhancers
Enhancers increase paracellular or transcellular peptide transport:
- Surfactants (sodium caprate, sodium glycocholate) transiently open tight junctions
- Chelating agents (EDTA) remove calcium from tight junction proteins
- Cell-penetrating peptides facilitate transcellular transport
Enzyme Inhibitors
Co-administration of protease inhibitors protects peptides during absorption:
- Aprotinin and Bowman-Birk inhibitor for serine proteases
- Bestatin for aminopeptidases
- Combined inhibitor cocktails provide broader protection
Formulation Approaches
Mnemonic: “SEAL” - Stability, Enhancement, Absorption, Liberation
| Strategy | Mechanism | Example |
|---|---|---|
| Enteric coating | Acid protection | Eudragit polymers |
| Nanoparticles | Protect and transport | PLGA nanoparticles |
| Liposomes | Membrane fusion | Phospholipid vesicles |
| Mucoadhesive systems | Prolonged GI residence | Chitosan formulations |
Successful Oral Peptides
Semaglutide (oral) demonstrates that oral peptide delivery is achievable with appropriate molecular modifications (fatty acid acylation for albumin binding and protease resistance) and absorption enhancers (SNAC).
Learning Tip
When designing oral peptides, simultaneously address enzymatic stability, membrane permeation, and acid stability. Optimizing only one barrier rarely achieves sufficient bioavailability. Consider whether the peptide’s size, charge, and stability profile make it a viable oral candidate.